Dr. Alexander Wyatt keynote at New Investigator Clinical Trials Course

Dr. Alexander Wyatt keynote speaker: New Investigator Clinical Trials Course

The CCTG New Investigator Clinical Trials Course is fast approaching and has already reached the maximum registration. The course will be held August 3 – 5, 2022 in Kingston, Ontario to provide and facilitate investigator education and training designed to educate new investigators from across the country about the essentials of clinical trial conduct in the Canadian research environment.

More >>
 

Matching ExCELLirate Canada funding from The Ontario Research Fund

It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".

More >>
 

CCTG at ASCO 2022

CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago

More >>
 

CCTG MA32 trial was published recently in the Journal of the American Medical Association

The findings of the CCTG MA32 trial were published recently in the Journal of the American Me

More >>
 

Planned trials

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

ALC7

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BLC5

MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

More >>

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

EN11

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

HD12

PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

More >>

HN13

Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

I242

Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

ME16

Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma

NE1

NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

PR23

Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy

SC28

The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

I242A

A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

CRC10

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

PR24

Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)

MA32R

Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer

Recently activated

CLC3E

Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

More >>

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

More >>

MEC6

Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma

More >>

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

More >>

PAC4

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
 
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma (ONLINE)

Nature Communications 13: 5020, 2022
Renouf DJ;Loree JM;Knox JJ;Topham JT;Kavan P;Jonker D;Welch S;Couture F;Lemay F;Tehfe M;Harb M;Aucoin N;Ko YJ;Tang PA;Ramjeesingh R;Meyers BM;Kim CA;Du P;Jia S;Schaeffer DF;Gill S;Tu D;O'Callaghan CJ;

More >>

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer (ONLINE)

J Clin Oncol : JCO, 2022
Topham JT;O'Callaghan CJ;Feilotter H;Kennecke HF;Lee YS;Li W;Banks KC;Quinn K;Renouf DJ;Jonker DJ;Tu D;Chen EX;Loree JM;

More >>

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma (ONLINE)

J Clin Oncol : JCO, 2022
Morschhauser F;Nastoupil L;Feugier P;Schiano de Colella J;Tilly H;Palomba ML;Bachy E;Fruchart C;Libby EN;Casasnovas RO;Flinn IW;Haioun C;Maisonneuve H;Ysebaert L;Bartlett NL;Bouabdallah K;Brice P;Ribrag V;Le Gouill S;Daguindau N;Guidez S;Pica GM;Garcia-Sancho AM;Lopez-Guillermo A;Larouche JF;Ando K;Gomes da Silva M;Andre M;Kalung W;Sehn LH;Izutsu K;Cartron G;Gkasiamis A;Crowe R;Xerri L;Fowler NH;Salles G;

More >>

Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA=2 cm Non-small Cell Lung Cancer (NSCLC): Results from an International Randomized Phase III Trial (CALGB 140503[Alliance])

, 2022
Wang X;Kozono D;Watt C;Landrenau R;Wigle D;Port J;Jones DR;Conti M;Ashrafi AS;Keenan R;Bauer T;Kohman LJ;Stinchcombe T;Vokes E;

More >>

RADICALS-HD: Reflections before the Results are Known (ONLINE)

Clin Oncol , 2022
Parker CC;Clarke NW;Catton C;Kynaston H;Cook A;Cross W;Davidson C;Goldstein C;Logue J;Maniatis C;Petersen PM;Neville P;Payne H;Persad R;Pugh C;Stirling A;Saad F;Parulekar WR;Parmar MKB;Sydes MR;

More >>

Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials (ONLINE)

The Oncol 27: e286 - e293, 2022
Wells JC;Sidhu A;Ding K;Smoragiewicz M;Heng DYC;Shepherd FA;Ellis PM;Bradbury PA;Jonker DJ;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour L;Monzon JG;

More >>

iRECIST and atypical patterns of response to immuno-oncology drugs (ONLINE)

J Immunother Cancer 10: e004849 - e004856, 2022
Ramon-Patino JL;Schmid S;Lau S;Seymour L;Gaudreau PO;Li JJN;Bradbury PA;Calvo E;

More >>